|
US2020399271A1
|
|
Xanthine analogs as potent anti-west nile viral agents
|
|
US2020399264A1
|
|
4-substituted-2-thiazole amides as antiviral agents
|
|
WO2020252380A2
|
|
2,4,7-substituted-7-deaza-2'-deoxy-2'-fluoroarabinosyl nucleoside and nucleotide pro-drugs and uses thereof
|
|
WO2020247633A1
|
|
Thiarabine- and thiarabine prodrug-based treatments
|
|
WO2020176266A1
|
|
Catalyst and method for producing ethylene
|
|
WO2020150040A1
|
|
Method of producing propylene glycol
|
|
US2020094184A1
|
|
High temperature thermochemical energy storage system
|
|
WO2020033317A1
|
|
Piperazine-2,5-diones as tgf-beta inhibitors
|
|
WO2019222497A1
|
|
2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases
|
|
AU2019256465A1
|
|
4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
|
|
US2020324483A1
|
|
In-Situ Monitoring of Additive Manufacturing Layer-by-Layer Build Using Ultrasonic Spectroscopy
|
|
WO2019183444A1
|
|
Hydrogenation and oligomerization process
|
|
WO2019164996A1
|
|
2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
|
|
WO2019133666A1
|
|
Triazolophthalazine compounds, use as anti-human immunodeficiency virus inhibitors of hiv vif-dependent degradation of apobec3
|
|
WO2019133574A2
|
|
Benzoannulene derivatives as antiviral agents
|
|
WO2019126567A1
|
|
Substituted heterocyclic-pyridinones as hiv-1 nef-hck inhibitors
|
|
WO2019126519A1
|
|
Continuous monitoring of selenium in water
|
|
US2020038402A1
|
|
Substituted quinazoline sulfonamides as thioredoxin interacting protein (txnip) inhibitors
|
|
WO2019084455A1
|
|
Dipeptide analogs as tgf-beta inhibitors
|
|
AU2018355531A1
|
|
Oxadiazoles and thiadiazoles as TGF-beta inhibitors
|
